The next trial followed the approach of collecting HSCT-donor-derived lymphocytes previously, either from mobilized PBSC or from lymphocyte apheresis and administering ADV-specific lymphocytes being a pre-emptive treatment
The next trial followed the approach of collecting HSCT-donor-derived lymphocytes previously, either from mobilized PBSC or from lymphocyte apheresis and administering ADV-specific lymphocytes being a pre-emptive treatment. focus on of prophylaxis or pre-emptive therapy targeted at stopping end-organ disease. Getting…